Background
==========

Hypertension is the major cause of global cardiovascular diseases (CVDs) and CVD mortality, and the economic burden related to hypertension is as much as 370 billion dollars \[[@b1-medscimonit-26-e923696],[@b2-medscimonit-26-e923696]\]. As the most populous country in the world, China's burden of hypertension is increasing accordingly \[[@b3-medscimonit-26-e923696]\]. In China, the prevalence of hypertension has been on the rise for the past 20 years and up to 27.9% of the adult population developed hypertension according to the latest national census data \[[@b4-medscimonit-26-e923696]\]. The disability-adjusted life years (DALY) as a result of hypertension in the Chinese population has reached 37.94 million, accounting for 12.0% of the total DALY and 63.5% of the CVDs-related DALY of CVDs \[[@b5-medscimonit-26-e923696],[@b6-medscimonit-26-e923696]\]. About 50% of strokes and 40% of myocardial infarctions are related to hypertension \[[@b7-medscimonit-26-e923696],[@b8-medscimonit-26-e923696]\]. With the aging of the population, the rapid development of urbanization, and changes in lifestyle and eating habits, the prevalence and burden of hypertension will continue to rise among the Chinese population.

Medication is the most effective intervention for blood pressure control. The over-activated renin-angiotensin system (RAS) is one of the major causes of hypertension \[[@b9-medscimonit-26-e923696]\]. In the latest European cardiovascular guideline \[[@b10-medscimonit-26-e923696]\], RAS inhibitors combined with calcium channel blocker (CCB) have been recommended as the primary choice for hypertension first-line medication. The Chinese Hypertension Intervention Efficacy (CHIEF) research report showed that when a small dose of amlodipine combined with RAS inhibitors was used for the first time, the blood pressure level of hypertension patients could be significantly reduced, and the control rate of hypertension can reach about 80%, suggesting that the combination of RAS inhibitors and CCB was one of the optimal antihypertensive regimens for hypertensive patients in China \[[@b11-medscimonit-26-e923696]\]. A systematic review based on randomized controlled trials (RCTs) also demonstrated that compared with other antihypertensive treatment options, RAS inhibitors combined with CCB were not only advantageous in the overall study population, but also in the subgroup \[[@b12-medscimonit-26-e923696]\]. The aforementioned research showed that the combination of RAS inhibitors and CCB as a first-line clinical treatment regimen could satisfy patients to a certain extent.

However, hypertension is a complex disease, and the individualized response to drugs is particularly prominent \[[@b13-medscimonit-26-e923696],[@b14-medscimonit-26-e923696]\]. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are 2 essential drug classes used to inhibit the RAS system. Studies have shown that even with the same diagnosis, treatment with the same RAS inhibitors could influence blood concentration and efficacy differently \[[@b15-medscimonit-26-e923696]\]. In clinical practice, with the help of a doctor, some patients could find a relatively reasonable medication plan by repeatedly adjusting the medication plan. Even so, some patients still might not attain the desired treatment effect after quantities of adjustments. Although, ACEI+CCB and ARB+CCB are all the first-line clinical treatment scheme in China, there are significant individual differences in the efficacy and side effects between the 2 schemes \[[@b16-medscimonit-26-e923696]\]. Therefore, we designed this real-world study in which we constructed a research cohort of hypertension medications and identified the effects of patient characteristics and comorbid diseases on drug selection, and we proposed a medication selection model under clinical application of renin-angiotensin inhibitor combined with calcium channel blocker (renin-angiotensin inhibitors selection model, RAISM) to provide references for clinical decision-making on antihypertensive medications.

Material and Methods
====================

Study design
------------

This study adopted a non-experimental comparative study design for analysis \[[@b17-medscimonit-26-e923696]\]. Due to the limitation of the research period and clinical resources, in order to reduce the influence of interference factors on research results, a retrospective cohort study method was used. The participants were grouped according to their exposure at a specific point in time (baseline point), and the outcome of participants in each group was observed. This study followed the Helsinki Declaration and was approved by the hospital ethics committee \[[@b18-medscimonit-26-e923696]\]. This study also followed the statement of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) \[[@b19-medscimonit-26-e923696]\].

Study data
----------

The study data were derived from the outpatient medical record system of a Chinese National Regional Medical Center from January 2018 to December in 2018. Inclusion criteria was as follows: patient was diagnosed with "hypertension", and the diagnostic criteria for the past year were in accordance with the 2010 Chinese guidelines for the management of hypertension \[[@b20-medscimonit-26-e923696]\]. There was no restriction on patient's age, medical history, or the clinic department where the patient was diagnosed. Exclusion criteria was as follows: continuing hypertensive patient and participant with incomplete data.

Patients received ACEI combined CCB medication plan (abbreviation: ACCB scheme) or ARB combined CCB medication plan (abbreviated: ARCB scheme), and patients were grouped according to their medication status.

Data collection
---------------

Data were collected through a 2-personnel independent approach, which were then checked by a third person. For any difference noticed in the collection process, the electronic medical record system would be further traced back and confirmed. The fields of data collection included patient medical record number (unique identification code), gender, age, height, weight, outpatient diagnosis, with or without diabetes, renal insufficiency, hyperlipidemia, brain ischemia, and coronary heart disease.

Data processing
---------------

According to the patient's medical record number, duplicate patients were removed, and only a patient's latest visit records and data information were retained. The medication scheme of each patient was sorted, and only patients who received the ACCB scheme or ARCB scheme were retained, and patients who had combined ACEI, ARB, and CCB treatment were excluded. The height and weight were converted into body mass index (BMI).

Statistical analysis
--------------------

All count data included in this study were described in the form of frequency and percentage, and mean and standard deviation were used to represent measurement data; If data met normal distribution, the *t*-test was performed for comparative analysis; If not, the Mann-Whitney U test was used for analysis and comparison; The comparative analysis of the count data was performed using the chi-square test or Fisher's exact probability method. When *P*-value \<0.05, the difference was considered to be statistically significant. The logistic regression model was used for univariate and multivariate analysis. According to the parameters of the statistical regression model, a RAISM was established utilizing the nomograph model technology; This study used the C-index and the re-correction curve to evaluate the discriminative ability of the RAISM, and used the receiver operating characteristic (ROC) curve analysis to calculate the cutoff value of the continuous variable, and used the decision curve to evaluate the clinical performance of the RAISM obtained in this study; In multivariate logistic analysis, by assuming that 5 factors were considered to be of clinical importance, and according to criteria that the number of observations was 10 times the number of variables, sample size of this study should not be less than 100 cases; All data analysis used R statistical software, version 3.5.2 (*<http://www.r-project.com>*).

Results
=======

Clinical characteristics of patients
------------------------------------

In this study, 1024 cases were initially retrieved and 213 of them were retained according to the inclusion and exclusion criteria. The case selection process is shown in [Figure 1](#f1-medscimonit-26-e923696){ref-type="fig"}. Patient-related fields were extracted including age, gender, height, weight, BMI, with or without diabetes, renal insufficiency, coronary heart disease, cerebral ischemia, and hyperlipidemia. Among the 213 study patients, 140 patients used ARB+CCB, with an average age of 60.73 years, accounting for 65.73%; 73 patients used ACEI+CCB, with an average age of 52.95 years, accounting for 34.27% (The detailed characteristics of patients are shown in [Table 1](#t1-medscimonit-26-e923696){ref-type="table"}).

Clinical features and concomitant conditions on drug selection
--------------------------------------------------------------

In order to compare the impact of patient's clinical features and comorbidities on medication choice for hypertension, we used single-factor logistic regression analysis to evaluate variables related to drug selection, including patient characteristics and clinical comorbidity parameters. Results of univariate logistic regression analysis are presented in [Table 2](#t2-medscimonit-26-e923696){ref-type="table"}. The report format was odds ratio (OR) with 95% confidence interval (CI). In the univariate logistic regression analysis of patient characteristics, age (for years, 0476 \[0.319--0.711\]), BMI for kg/m^2^ (1.274 \[1.001--1.622\]), and elderly patient (for ≥65 versus \<65 years, 0.365 \[0.180--0.743\]) were the discriminative factors of drug selection; In the univariate logistic regression analysis of clinical comorbidity parameters, diabetes mellitus (for with versus without, 0.471 \[0.203--1.092\]), renal insufficiency (for with versus without, 0.542 \[0.268--1.094\]), and hyperlipidemia (for with versus without, 0.270 \[0.100--0.728\]) were the discriminative factors that influence drug choice.

When BMI was a continuous variable, it was a discriminative factor for drug selection. However, there was no statistical difference between 2 groups when they were divided according to the BMI cutoff of 24 kg/m^2^ (overweight) (OR=1.556, 95% CI: 0.856--2.827, *P*=0.147), suggesting that the critical value indicating overweight is not the cutoff value that affects the patient's medication. Therefore, we identified the cutoff value through the ROC curve, and the results showed that the cutoff value of BMI was 23.805 kg/m^2^ ([Figure 2](#f2-medscimonit-26-e923696){ref-type="fig"}). To be specific, univariate logistic regression demonstrated that statistical differences appeared between the 2 groups (OR=1.845, 95% CI: 1.02--3.33, *P*=0.042) when divided by the BMI of 23.805 kg/m^2^.

Development and validation of a RAISM base on study cohort
----------------------------------------------------------

All variables in this study were patients' characteristic parameters before medication selection, including demographic characteristics and clinical comorbidity parameters. On the basis of univariate logistic regression analysis, independent factors that influence drug selection were incorporated into the multifactor logistic regression analysis, generating the model construction parameters. Through the application of multivariate logistic regression analysis, it was found that the conditions of whether patients were elderly, with or without renal insufficiency, and with or without hyperlipidemia were independent discriminative factors which affect drug selection, and the OR and 95% CI were 0.341 (0.161--0.719), 0.493 (0.234--1.040), and 0.288 (0.103--0.805), respectively, as shown in [Table 3](#t3-medscimonit-26-e923696){ref-type="table"}.

Model construction parameters were used to generate a RAISM ([Table 3](#t3-medscimonit-26-e923696){ref-type="table"}). The internal verification was utilized to verify the discriminative ability of the model. The internally verified C-index was 0.699 (0.680--0.718). The calibration curve for the selection and actual results of the RAISM was shown in [Figure 3](#f3-medscimonit-26-e923696){ref-type="fig"} (Mean squared error=0.002), which indicated that the discriminative ability on the RAISM was good.

Application and clinical manifestations of RAISM
------------------------------------------------

In order to improve the practicality of the RAISM, the Youden index (sensitivity+specificity -- 1) was used to calculate the best cutoff value of the nomogram score, and the physicians can refer to the cutoff value to set the threshold probability. The cutoff value under the maximum Youden index was 316 points (the corresponding selection probability is 58%), and under this circumstance, the data of 213 patients were divided into ACCB group and ARCB group, with a sensitivity of 60.3% and a specificity of 73.6%.

The decision curve was further used to compare the net benefit value of the RAISM under various threshold probabilities. The decision curve shown in [Figure 4](#f4-medscimonit-26-e923696){ref-type="fig"}, from which, it can be seen that compared with the 2 extreme cases (assuming that all patients used one treatment regimen or no medication), within the threshold probability range of 21% to 57%, there was a net benefit when implementing medication guidance on the basis of the RAISM.

Discussion
==========

The regimen of RAS inhibitors combined with CCB has been widely used to treat hypertension, especially for patients with hypertension in combination with diabetes \[[@b21-medscimonit-26-e923696]\]. This regimen was more often recommended for reducing the incidence and mortality of nephropathy and CVDs \[[@b22-medscimonit-26-e923696],[@b23-medscimonit-26-e923696]\]. Based on the results of RCTs, there were differences in the treatment effect between subgroups treated with different RAS inhibitors \[[@b24-medscimonit-26-e923696]\]. Clinically, it is not clear how to choose different RAS inhibitors based on the differences of patient characteristics. Therefore, we designed this real-world study so as to provide a reference for physicians to make a reasonable selection of RAS inhibitors.

In recent years, the establishment of statistical prediction models has become a hot spot in medication clinical studies \[[@b25-medscimonit-26-e923696],[@b26-medscimonit-26-e923696]\]. The nomogram, as a highly individualized visual prediction tool, has been widely adopted in the prediction and decision-making of clinical medication selection and various other important events, including hypertension, diabetes, and nephropathy \[[@b27-medscimonit-26-e923696],[@b28-medscimonit-26-e923696]\]. The main feature of the nomogram is to create a visual graph that can accurately calculate the clinical time probability according to the parameters of the statistical regression model. Therefore, we used the nomogram technique to construct a model for selecting medications for hypertension.

This study established a nomogram model of medication selection on the basis of demographic characteristics and concomitant conditions of both groups of patients who received ACCB and ARCB regimen, respectively. The main findings of this study included: 1) whether the patient was elderly or not, with or without nephropathy, and with or without hyperlipidemia were independent discriminative factors affecting RAS inhibitors selection in hypertensive patients; and 2) the better medication regimen could be determined by using the RAISM based on patients' characteristic score.

The results of univariate logistic regression analysis indicated that the age, BMI of the patient, and whether he or she was elderly, whether the patient had diabetes, renal insufficiency, or hyperlipidemia were the discriminative factors affecting the choice of hypertension drugs. Results of multivariate logistic regression analysis also suggested that whether the patient was elderly, had renal insufficiency, or hyperlipidemia were the discriminative factors affecting the choice of hypertension drugs. Hence, whether the patient was elderly, accompanied by renal insufficiency, or hyperlipidemia were independent factors that influence the choice of RAS inhibitor drugs. We classified our patients into overweight and non-overweight groups according to the BMI cutoff of 24 kg/m^2^, but no statistical difference was detected between the 2 groups \[[@b29-medscimonit-26-e923696],[@b30-medscimonit-26-e923696]\]. Therefore, we further calculated the optimal cutoff value that affects the choice of RAS inhibitor drugs through the ROC curve to be 23.805 kg/m^2^. At the same time, considering the co-linear relationship between the patient's age and whether they are senile, and based on the simplicity of the physician's operation, we retained the inclusion parameters of whether the patient is senile.

Based on the model composition parameters attained from logistic regression, whether the patient is senile, whether the BMI is less than 23.805 kg/m^2^, whether with diabetes, renal insufficiency and hyperlipidemia, we established a hypertension drug selection nomogram model which could calculate the discrimination probability of drug selection for each patient according to their characteristics and comorbidities. Physicians can conveniently acquire a quantitative medication selection probability based on this medication selection model and determine which therapeutic regimen to choose for the patient. Meanwhile, in order to facilitate the use of the scoring mechanism of the RAISM, we determined the optimal cutoff value of 316 points through the Youden index, as a reference for the physician to judge the threshold probability.

In clinical pharmacology, there some differences in the therapeutic targets of different RAS inhibitors, which will inevitably lead to certain differences in clinical application \[[@b31-medscimonit-26-e923696]\]. The mechanism of ACEI is to inhibit RAS system and the conversion from angiotensin I (Ang I) to Ang II, to reduce the level of Ang II in plasma, reducing the secretion of aldosterone and the retention of water and sodium in the body, inducing the increase of prostacyclin (PGI2) and intravascular nitric oxide (NO), so as to achieve dilating blood vessels, reducing peripheral circulation resistance, cardiac anteroposterior load, proteinuria and improving renal blood flow \[[@b32-medscimonit-26-e923696],[@b33-medscimonit-26-e923696]\]. ARB works by blocking AT1 in the 4 Ang II receptor subtypes (AT1, AT2, AT3, and AT4) to inhibit vasoconstriction and myocardial contraction, to reduce pituitary hormones, aldosterone secretion, and water and sodium retention \[[@b34-medscimonit-26-e923696],[@b35-medscimonit-26-e923696]\]. Current drug treatment for hypertension is based more on the evidence at population level. There are no clear guidelines for the selection of ACCB or ARCB in clinical guidelines \[[@b36-medscimonit-26-e923696]\]. In most cases, if patients use one drug and if found to be intolerant, will then be changed to another drug. Therefore, rational application of RAS inhibitors accomplished through individualized methods has certain guiding significance for clinical practice.

Real-world data have become an important source of evidence for healthcare decisions \[[@b37-medscimonit-26-e923696]\]. In 2018, the US FDA incorporated real-world research evidence into the drug approval process \[[@b38-medscimonit-26-e923696]\]. In 2019, the China Drug Evaluation Center drafted the "Basic Considerations of Real-World Evidence Supporting Drug Development (Draft for Comment)" to estimate the use of real-world evidence in evaluating the application scenarios and principles of drug effectiveness and safety. This study provides clinical reference through real-world research design; it used the C-index to evaluate the predictive power of the RAISM. The results suggested that the RAISM established in this study predicted a C-index of 0.699 in all samples, which was good. The actual occurrence and predicted occurrence are fairly consistent. The decision curve analysis showed that within the threshold probability range of 21--57%, the application of a RAISM would bring net benefit. The above analysis results have repeatedly confirmed that the RAISM provided by this study has reference value for the drug decision for RAS inhibitors.

There are some limitations in this study. Firstly, this study was a single-center study, so that certain homogeneity might exist among the hypertensive patients, and more RCTs and multi-center studies are required to verify the results of this study. Secondly, this study was a retrospective study, which means the sequential order of exposure and outcome was unavailable, and the causal relationship could not be determined. Therefore, this study did not make judgment on the treatment outcome of different medication regimens. The rationality of medication was based on the rationality of prescription, and bias might exist in the results. Thirdly, this study lacked information on blood pressure monitoring data, and we only considered the complication data of heart, brain, kidney, and vascular. Further prospective studies are needed to validate the results of this study.

Conclusions
===========

In summary, whether the patient was senile, with or without renal insufficiency, and with or without hyperlipidemia were independent discriminative factors that affect the clinical selection of different medication regimens for RAS inhibitors combined CCB. In addition, the RAISM established based on nomogram technology has good predictive power and can bring clinical net benefits, but RCTs and multi-center studies are required to confirm this conclusion.
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###### 

Participant characteristics (n=213).

                                ACEI+CCB (n=73)   ARB+CCB (n=140)   Total (n=213)   *P*-value
  ----------------------------- ----------------- ----------------- --------------- -----------
  Age (years)                   52.95±11.99       60.73±14.90       58.06±14.43     0.001
  Sex                                                                               0.560
   Male                         39 (53.42%)       82 (58.57%)       121 (56.81%)    
   Female                       34 (46.58%)       58 (41.43%)       92 (43.19%)     
  BMI                           24.05±5.64        22.81±3.07        23.24±4.16      0.039
  Height (cm)                   165.11±6.54       165.37±6.52       165.29±6.51     0.783
  Weight (kg)                   65.47±15.34       62.55±10.04       63.55±12.16     0.096
  Overweight (BMI \>24)                                                             0.165
   Yes                          28 (38.36%)       40 (28.57%)       68 (31.92%)     
   No                           45 (61.64%)       100 (71.43%)      145 (68.08%)    
  Elderly patient (≥65 years)                                                       0.004
   Yes                          12 (16.44%)       49 (35.00%)       61 (28.64%)     
   No                           61 (83.56%)       91 (65.00%)       152 (71.36%)    
  Diabetes mellitus                                                                 0.088
   Yes                          8 (10.96%)        29 (20.71%)       37 (17.37%)     
   No                           65 (89.04%)       111 (79.29%)      176 (82.63%)    
  Renal insufficiency                                                               0.096
   Yes                          13 (17.81%)       40 (28.57%)       53 (24.88%)     
   No                           60 (82.19%)       100 (71.43%)      160 (75.12%)    
  Hyperlipidemia                                                                    0.006
   Yes                          5 (6.85%)         30 (21.43%)       35 (16.43%)     
   No                           68 (93.15%)       110 (78.57%)      178 (83.57%)    
  Cerebral ischemia                                                                 0.338
   Yes                          2 (2.74%)         9 (6.43%)         11 (5.16%)      
   No                           71 (97.26%)       131 (93.57%)      202 (94.84%)    
  Coronary disease                                                                  0.999
   Yes                          6 (8.22%)         13 (9.29%)        19 (8.92%)      
   No                           67 (91.78%)       127 (90.71%)      194 (91.08%)    

ACEI -- angiotensin-converting enzyme inhibitor; ARB -- angiotensin receptor antagonist; CCB -- calcium channel blocker; BMI -- body mass index.

###### 

Univariate logistic regression analysis of drug selection based on clinical data in the target queue.

  Variable                                 OR      95% CI         *P*-value
  ---------------------------------------- ------- -------------- -----------
  Age (years)                              0.476   0.319--0.711   \<0.001
  Sex (Female *vs.* Male)                  1.233   0.697--2.179   0.472
  BMI                                      1.274   1.001--1.622   0.049
  Height (cm)                              0.938   0.607--1.451   0.774
  Weight (kg)                              1.260   0.952--1.667   0.106
  Overweight (\>24 *vs.* ≤24)              1.556   0.856--2.827   0.147
  Elderly patient (≥65 *vs.* \<65 years)   0.365   0.180--0.743   0.005
  Diabetes mellitus (yes *vs.* no)         0.471   0.203--1.092   0.079
  Renal insufficiency (yes *vs.* no)       0.542   0.268--1.094   0.087
  Hyperlipidemia (yes *vs.* no)            0.270   0.100--0.728   0.010
  Cerebral ischemia (yes *vs.* no)         0.410   0.086--1.950   0.262
  Coronary disease (yes *vs.* no)          0.875   0.318--2.406   0.796
  BMI (\>23.805 *vs.* \<23.805)            1.845   1.021--3.333   0.042

OR -- odd ratio; CI -- confidence interval; BMI -- body mass index.

###### 

Multivariate logistic regression analysis of drug selection based on clinical data in the target queue.

  Variable                                 [β](#tfn3-medscimonit-26-e923696){ref-type="table-fn"}   OR      95% CI         *P*-value
  ---------------------------------------- -------------------------------------------------------- ------- -------------- -----------
  Elderly patient (≥65 *vs.* \<65 years)   −1.076                                                   0.341   0.161--0.719   0.005
  Diabetes mellitus (yes *vs.* no)         0.484                                                    0.616   0.251--1.510   0.290
  Renal insufficiency (yes *vs.* no)       −0.706                                                   0.493   0.234--1.040   0.063
  Hyperlipidemia (yes *vs.* no)            −1.243                                                   0.288   0.103--0.805   0.018
  BMI (\>23.805 *vs.* \<23.805)            0.323                                                    1.382   0.732--2.606   0.318

β -- intercept value; OR -- odd ratio; CI -- confidence interval; BMI -- body mass index.
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